Adult: For the treatment of acute attacks in patients with C1-esterase inhibitor deficiency: 30 mg as a single dose via SC inj over ≥30 seconds. Additional doses may be given at intervals of ≥6 hours if relief is insufficient or symptoms recur. Max: 3 doses (90 mg) daily. Child: Dosage recommendations may vary among countries and individual products. Refer to specific product guidelines.
Patient with acute ischaemic heart disease or unstable angina pectoris, recent stroke. Advise patients with laryngeal hereditary angioedema (HAE) attacks to seek immediate medical attention in an appropriate healthcare facility in addition to treatment with icatibant. Children. Pregnancy and lactation.
Significant: CNS depression. Gastrointestinal disorders: Nausea. General disorders and administration site conditions: Pyrexia, inj site reactions (e.g. bruising, burning, haematoma, erythema, hypoaesthesia, irritation, numbness, oedema, pain, pressure sensation, swelling, urticaria, warmth). Investigations: Increased transaminases and creatine phosphokinase, prolonged prothrombin time. Nervous system disorders: Dizziness, headache. Skin and subcutaneous tissue disorders: Erythema, pruritus, rash.
This drug may cause lethargy, tiredness, fatigue, somnolence, or dizziness; if affected, do not drive or operate machinery.
Monitor symptom relief; laryngeal symptoms or airway obstruction.
May decrease the antihypertensive effect of ACE inhibitors.
Description: Icatibant, a synthetic decapeptide, is a selective competitive inhibitor at the bradykinin type 2 (B2) receptor. Bradykinin is a vasodilator thought to be responsible for the characteristic HAE symptoms of localised swelling, inflammation, and pain. Competitive inhibition of the bradykinin B2 receptor reduces the vasodilatory effects of excess bradykinin, thereby treating the symptoms associated with the acute attacks of HAE. Onset: 50% decrease in symptoms: Approx 2 hours. Duration: Approx 6 hours. Pharmacokinetics: Absorption: Bioavailability: Approx 97%. Time to peak plasma concentration: 0.75 hours. Distribution: Plasma protein binding: 44%. Metabolism: Extensively metabolised by proteolytic enzymes to inactive metabolites. Excretion: Mainly via urine (<10% as unchanged drug). Elimination half-life: Approx 1-2 hours.
Store between 2-25°C. Do not freeze. Protect from light. Follow applicable procedures for receiving, handling, administration, and disposal.
B06AC02 - icatibant ; Belong to the class of drugs used in the treatment of hereditary angioedema.
Anon. Icatibant Acetate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 16/12/2021.Anon. Icatibant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 16/12/2021.Buckingham R (ed). Icatibant Acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/12/2021.Firazyr Solution for Injection in Pre-filled Syringe 30 mg/3 mL (Takeda Pharmaceuticals [Hong Kong] Ltd). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 16/12/2021.Icatibant 30 mg Solution for Injection in Pre-filled Syringe (Kensington Pharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 16/12/2021.Icatibant Acetate Injection, Solution (Apotex Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 16/12/2021.Sajazir Injection (Cycle Pharmaceuticals Ltd-UK). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 16/12/2021.Takeda New Zealand Limited. Firazyr 30 mg/3 mL Solution for Injection data sheet 28 September 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 16/12/2021.